Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

RheumPAC: A Wise Investment to Let Your Voice Be Heard in Washington, D.C.

From the College  |  April 5, 2021

ACR/ARP members share why they support the ACR’s nonpartisan political action committee and see it as an investment in the future of rheumatology.

Secukinumab Effective Across the Spectrum of Psoriatic Arthritis

Mary Beth Nierengarten  |  April 5, 2021

A posthoc analysis confirms patients with active psoriatic arthritis (PsA) taking secukinumab experience improvement in all signs and symptoms of PsA as measured by the GRAPPA-OMERACT disease activity core domains.

Channel Policy Frustrations into Advocacy to Improve Patient Care

Leslie Mertz, PhD  |  April 2, 2021

Frustrated with policies he viewed as obstacles to optimal patient care, Howard Yang, MD, RhMSUS, tried advocacy as a way to turn those feelings into positive action—an eye-opening and rewarding experience he strongly recommends.

Combined Conservative Treatments Improve Function in Thumb-Base Osteoarthritis

Lisa Rapaport  |  April 1, 2021

(Reuters Health)—People with thumb-base osteoarthritis (OA) who receive a combination of conservative treatments, including education in self-management, ergonomics and hand exercises, may experience clinically meaningful improvements in hand function, a study suggests. Researchers randomized 204 people with thumb-base OA (1:1) to receive education on self-management and ergonomics alone (comparator) or in combination with a base-of-thumb…

Women Are Underrepresented in NIH Study Sections & Receive Less Funding than Men

Lara C. Pullen, PhD  |  April 1, 2021

Women remain underrepresented in research and may receive less funding than men, according to a recent study that describes differences in sex representation among U.S. National Institutes of Health study sections.

Global Prevalence & Burden of Musculoskeletal Disorders

Arthritis & Rheumatology  |  March 31, 2021

Musculoskeletal disorders pose a large burden globally, but that burden is often underappreciated. Safiri et al. set out to provide a global overview of this burden, reporting the levels and trends of prevalence, deaths and disability-adjusted life years due to musculoskeletal disorders according to age, sex and sociodemographic factors.

Total Knee Replacement Cost-Effective, Even with Obesity & Comorbidities

Lisa Rapaport  |  March 29, 2021

(Reuters Health)—Total knee replacement surgery can be a cost-effective procedure for patients with severe obesity and osteoarthritis (OA), even when they also have comorbidities such as cardiovascular disease or type 2 diabetes, a new study suggests. Researchers did a cost-benefit analysis for two patient populations (over 65 years, and age 50 to 65) who had…

COVID-19 Vaccination Strategies Suggested for Patients on Anti-Rheumatic Immunosuppressive Therapy

Marilynn Larkin  |  March 29, 2021

NEW YORK (Reuters Health)—U.K. experts propose evidence-based management strategies for rheumatology patients on immunosuppressive therapy, including delaying/postponing rituximab, as appropriate. “The aim of this viewpoint article is to outline the existing data on the effect of anti-rheumatic therapy on vaccine responses in patients with inflammatory arthritis and to formulate a possible pragmatic strategy for the…

FDA Approves Tocilizumab to Treat Systemic Sclerosis-Associated ILD

Michele B. Kaufman, PharmD, BCGP  |  March 25, 2021

Subcutaneous tocilizumab is the first biologic agent approved by the FDA treat patients with systemic sclerosis-associated interstitial lung disease.

Non-Invasive Vagus Nerve Stimulation Tolerated, Effective for Rheumatoid Arthritis

Lisa Rapaport  |  March 24, 2021

(Reuters Health)—Non-invasive vagus nerve stimulation is safe and effective as an intervention for rheumatoid arthritis (RA), a small proof-of-concept study suggests. The study enrolled 35 patients with active RA and an inadequate response to therapy with disease-modifying anti-rheumatic drugs (DMARDs). All DMARDS were discontinued four weeks prior to the trial. For the study, all participants…

  • « Previous Page
  • 1
  • …
  • 153
  • 154
  • 155
  • 156
  • 157
  • …
  • 816
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences